Drug combo of Herceptin and Tykerb boosts survival in advanced breast cancer
In San Antonio, a study of 300 patients shows the Herceptin Tykerb combo extends median survival to 61 weeks versus 41 weeks for Tykerb alone. The trial targets HER-2 positive tumors with two drugs acting inside and on the cell surface.
MENTIONED IN THIS ARTICLE
San Antonio
Jennifer Litton
University of Texas
M. D. Anderson Cancer Center
Litton
Herceptin
Tykerb
Kimberly Blackwell
Duke University
GlaxoSmithKline PLC
Genentech
Blackwell
Stephanie Will
U.S. Army
Fort Bragg
N.C
Will
Eric Winer
Dana- Farber Cancer Center
Boston
Economic reports raise hopes for global recovery
Washington based report signals strengthening of the fragile recovery as consumer spending and stock rebuilding improve. November retail sales rose 1.3 percent the strongest gain since August, though economists warn unemployment, income growth and credit tightness could slow future demand and extend a tepid holiday season.
MENTIONED IN THIS ARTICLE
Washington
Commerce Department
Chris Rupkey
Bank of Tokyo- Mitsubishi
New York
Paul Dales
Capital Economics
ShopperTrak
Also Mentioned on This Page
Etry Weller
Power Tools
Skadgoace
Black and Decker
ASME
Spmn
Makita
Maktec
Garden City
Fleming
Rang Ewlley
Ste
Adveake Selekt
Toys R Us
J.C. Penney